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Conclusions: The aforementioned clinical outcomes and com-
parative analysis is essential for furthering our understanding of
the factors which inﬂuence patient outcomes in the treatment of
cartilage injury by autologous chondrocyte implantation therapy
such as MACI.
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Purpose: A 79% reduction in upper gastrointestinal (GI) ul-
cer complications has been reported for lumiracoxib compared
with nonsteroidal anti-inﬂammatory drugs (NSAIDs) (naproxen
or ibuprofen) over 52 weeks in the non-aspirin population of
the Therapeutic Arthritis Research and Gastrointestinal Event
Trial (TARGET). However, guidelines indicate that these agents
should be used for the shortest possible duration. We investi-
gated how early after the start of treatment a signiﬁcant beneﬁt
of lumiracoxib could be detected in TARGET.
Methods: TARGET randomized 18 325 patients >50 years of
age with osteoarthritis (OA) to receive lumiracoxib 400 mg once
daily (4x the recommended dose for OA) vs ibuprofen 800 mg
three times daily or naproxen 500 mg twice daily for 52 weeks in
one of two sub-studies. Randomization was stratiﬁed for age and
low-dose aspirin use. The primary analysis population included
patients not taking low-dose aspirin, comprising n=6950 patients
treated with lumiracoxib and n=6968 with NSAIDs (naproxen,
n=3537; ibuprofen, n=3431). The primary endpoint was the cu-
mulative incidence of blindly and independently adjudicated def-
inite or probable upper GI ulcer complications. The secondary
endpoint was the incidence of deﬁnite or probable upper GI ulcer
complications and symptomatic ulcers (all ulcers). In these anal-
yses, pointwise 95% conﬁdence intervals (CI) were generated
for the between-treatment differences in Kaplan-Meier estimates
(KMEs) for all ulcers and ulcer complications in the non-aspirin
population.
Results: Based on the upper 95% CIs for the difference in
Kaplan-Meier estimates, in the non-aspirin population there was
a signiﬁcant reduction in all ulcers by Day 8 with lumiracoxib
compared with NSAIDs. For ulcer complications, a signiﬁcant re-
duction with lumiracoxib compared with NSAIDs occurred by Day
16. When analyzed by sub-study, the advantage of lumiracoxib
on all ulcers occurred as early as by Day 6 versus naproxen
(Figure 1) and by Day 32 versus ibuprofen. For ulcer complica-
tions, a signiﬁcant reduction was seen with lumiracoxib by Day
14 versus naproxen and Day 33 versus ibuprofen.
Abstract 260 – Table 1. Efﬁcacy of lumiracoxib in the disease severity subgroups at 13 week
Efﬁcacy variable Pair wise Comparison High severity group Medium severity group Low severity group
Estimated difference P-value Estimated difference P-value Estimated difference P-value
(95% CI of difference) (95% CI of difference) (95% CI of difference)
OA pain Lumiracoxib vs placebo -9.30 (-13.25,-5.34) <0.001 -5.48 (-8.41,-2.55) <0.001 -4.74 (-8.44,-1.03) 0.012
Celecoxib vs placebo -6.70 (-11.22,-2.19) 0.004 -4.76 (-8.15,-1.38) 0.006 -4.74 (-9.03,-0.45) 0.030
Lumiracoxib vs celecoxib -2.59 (-6.44,1.25) 0.186 -0.71 (-3.67,2.24) 0.636 0.00 (-3.70,3.71) 0.998
Patient’s global assessment Lumiracoxib vs placebo -9.83 (-13.74,-5.93) <0.001 -8.09 (-10.99,-5.20) <0.001 -4.21 (-7.87,-0.55) 0.024
of disease activity Celecoxib vs placebo -6.63 (-11.09,-2.18) 0.004 -6.10 (-9.45,-2.75) <0.001 -3.47 (-7.72,0.77) 0.109
Lumiracoxib vs celecoxib -3.20 (-7.00,0.60) 0.099 -1.99 (-4.91,0.93) 0.181 -0.74 (-4.40,2.93) 0.694
WOMAC™ total score Lumiracoxib vs placebo -8.08 (-10.86,-5.30) <0.001 -5.26 (-7.32, -3.19) <0.001 -4.11 (-6.72,-1.50) 0.002
Celecoxib vs placebo -5.62 (-8.79,-2.44) <0.001 -4.94 (-7.32,-2.56) <0.001 -3.24 (-6.26,-0.22) 0.036
Lumiracoxib vs celecoxib -2.47 (-5.17,0.24) 0.074 -0.32 (-2.40,1.77) 0.767 -0.87 (-3.48,1.74) 0.513
Figure 1
Conclusions: The long-term GI beneﬁt of lumiracoxib compared
with traditional NSAIDs has been demonstrated previously. How-
ever, even when given for short periods, the selective COX-2
inhibitor lumiracoxib appears to have signiﬁcant GI safety advan-
tages over nonselective NSAIDs.
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Purpose: To evaluate if the efﬁcacy of lumiracoxib 100 mg od and
celecoxib 200 mg od differed in patients with knee osteoarthritis
(OA) as a function of baseline disease severity.
Methods: Data from two 13-week, multicenter, randomized,
double-blind, double-dummy, placebo-controlled studies compar-
ing lumiracoxib 100 mg od with celecoxib 200 mg od and placebo
were combined for efﬁcacy analysis based on baseline disease
severity. The co-primary endpoints included assessment of OA
pain intensity in the target knee (VAS), patient’s global assess-
ment of disease activity (VAS) and WOMAC™ LK3.1 total score
at study end. Disease severity at baseline was deﬁned as high,
medium, or low using the median of the baseline values for
each of the three primary assessments. A patient was classiﬁed
with high baseline disease severity if all 3 baseline values were
greater than their respective median, medium baseline disease
severity if 1 or 2 baseline values were greater than their median
and low baseline disease severity if none of the 3 baseline
